Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05667142 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
A Phase 3 study of Primary Generalized Tonic-Clonic Seizures, sponsored by Xenon Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT05667142 is a Phase 3 study of Primary Generalized Tonic-Clonic Seizures that is actively recruiting participants, run by Xenon Pharmaceuticals. The registered enrollment target is 160 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT05667142, a Phase 3 study of Primary Generalized Tonic-Clonic Seizures, is actively recruiting participants, sponsored by Xenon Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XEN1101
Study Locations (20)
Florida
- Mayo Clinic Florida - Jacksonville
- Serenity Research Center, LLC - Miami
- Research Institute of Orlando, LLC - Orlando
- Panhandle Research and Medical Clinic - Pensacola
- Medsol Clinical Research Center Harbor Professional Centre - Port Charlotte
- University of South Florida - Tampa
- Encore Medical Research of Weston, LLC - Weston
California
- Brain Science Research Institute - Los Angeles
- University of California, Irvine - Health Neurology Services - Orange
- University California, Davis Clinical & Translation Science Center Clinical Research (CCRC) - Sacramento
Georgia
- Emory Brain Health Center - Atlanta
- Children's Healthcare of Atlanta - Atlanta
- Georgia Neurology & Sleep Medicine Associates - Suwanee
Arizona
- Xenoscience - Phoenix
- University of Arizona - Health Science Center - Tucson
Alabama
- University of Alabama - Strada Patient Care Center, Neurology - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Hawaii
- Hawaii Pacific Neuroscience, Comprehensive Epilepsy Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05667142
The ClinicalTrials.gov registry entry for NCT05667142 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Generalized Tonic-Clonic Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05667142 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05667142 about?
NCT05667142 is a clinical study titled "A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
What is the current status of trial NCT05667142?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2023-02-14. Estimated completion is 2027-06.
What conditions does trial NCT05667142 study?
This clinical trial studies the following conditions: Primary Generalized Tonic-Clonic Seizures.
What interventions are being tested in trial NCT05667142?
The interventions under investigation include: Placebo (DRUG), XEN1101 (DRUG).
Who is sponsoring clinical trial NCT05667142?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05667142 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.